GGHC
ESPR

Gilder Gagnon Howe & Co’s Esperion Therapeutics ESPR Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,006
Closed -$12K – 403
2021
Q3 		$12K Hold
1,006
– – ﹤0.01% 400
2021
Q2 		$21K Hold
1,006
– – ﹤0.01% 388
2021
Q1 		$28K Sell
1,006
-118
-10% -$3.48K ﹤0.01% 364
2020
Q4 		$29K Sell
1,124
-4
-0.4% -$120 ﹤0.01% 318
2020
Q3 		$42K Hold
1,128
– – ﹤0.01% 319
2020
Q2 		$58K Hold
1,128
– – ﹤0.01% 290
2020
Q1 		$36K Sell
1,128
-4
-0.4% -$211 ﹤0.01% 261
2019
Q4 		$68K Hold
1,132
– – ﹤0.01% 274
2019
Q3 		$41K Hold
1,132
– – ﹤0.01% 273
2019
Q2 		$53K Hold
1,132
– – ﹤0.01% 280
2019
Q1 		$45K Sell
1,132
-468
-29% -$21K ﹤0.01% 268
2018
Q4 		$74K Sell
1,600
-3
-0.2% -$145 ﹤0.01% 254
2018
Q3 		$71K Sell
1,603
-71
-4% -$3.26K ﹤0.01% 276
2018
Q2 		$66K Sell
1,674
-13
-0.8% -$657 ﹤0.01% 270
2018
Q1 		$122K Sell
1,687
-2
-0.1% -$147 ﹤0.01% 270
2017
Q4 		$111K Hold
1,689
– – ﹤0.01% 279
2017
Q3 		$85K Hold
1,689
– – ﹤0.01% 266
2017
Q2 		$78K Sell
1,689
-51
-3% -$1.88K ﹤0.01% 269
2017
Q1 		$61K Sell
1,740
-13
-0.7% -$298 ﹤0.01% 264
2016
Q4 		$22K Sell
1,753
-2,008
-53% -$23.9K ﹤0.01% 260
2016
Q3 		$52K Sell
3,761
-69
-2% -$782 ﹤0.01% 258
2016
Q2 		$38K Sell
3,830
-50
-1% -$829 ﹤0.01% 265
2016
Q1 		$66K Sell
3,880
-203
-5% -$3.27K ﹤0.01% 218
2015
Q4 		$91K Sell
4,083
-1,614
-28% -$40.7K ﹤0.01% 226
2015
Q3 		$134K Sell
5,697
-814,008
-99% -$51.1M ﹤0.01% 228
2015
Q2 		$67M Buy
819,705
+13,715
+2% +$1.34M 0.88% 37
2015
Q1 		$74.6M Buy
805,990
+775,589
+2,551% +$50.1M 1.04% 30
2014
Q4 		$1.23M Buy
+30,401
New +$931K 0.02% 196

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Gilder Gagnon Howe & Co's ESPR Position: Q4 2021 in Review

Gilder Gagnon Howe & Co sold out of Esperion Therapeutics (ESPR) in Q4 2021, closing a stake of 1,006 shares — an estimated $12K sold.

Gilder Gagnon Howe & Co first reported a position in ESPR in Q4 2014 and held it in 28 quarters. The position peaked at $74.6M in Q1 2015. 133 funds tracked by Wall St. Rank hold ESPR as of Q4 2021.

  • Gilder Gagnon Howe & Co reported no remaining Esperion Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 1,006 Esperion Therapeutics shares in Q4 2021, an estimated $12K.
  • Gilder Gagnon Howe & Co first reported a position in Esperion Therapeutics in Q4 2014 and held it in 28 quarters.
  • Gilder Gagnon Howe & Co's Esperion Therapeutics position peaked at $74.6M in Q1 2015.
  • 133 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2021.

Based on Gilder Gagnon Howe & Co's 13F filing for Q4 2021, filed 14 Feb 2022.